Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Observational
SUMMARY
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101.
• Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Locations
Other Locations
Republic of Korea
Seoul National University Hospital
RECRUITING
Seoul
Severance Hospital
COMPLETED
Seoul
Contact Information
Primary
Jae Hee Cheon, Ph D
GENIUSHEE@yuhs.ac
Time Frame
Start Date: 2016-11-16
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 9
Treatments
ALLO-ASC-CD injection
Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
Authors
Won Ho Kim
Related Therapeutic Areas
Sponsors
Leads: Anterogen Co., Ltd.